FARMACIA HOSPITALARIA最新文献

{"title":"Designing a patient onboarding in a multidisciplinary severe asthma unit.","authors":"Hilario Martínez-Barros, María Muñoz-García, Darío Antolín-Amérigo, Silvia Sánchez-Cuéllar, Ana Morales-Tirado, Ana de-Andrés-Martín, Gonzalo de-Los-Santos-Granados, Laura Yeguas-Ramírez, Enrique Blitz-Castro, Alfonso Santamaría-Gadea, Belén de-la-Hoz-Caballer, Sagrario Martín-Aragón, David González-de-Olano, Ana María Álvarez-Díaz","doi":"10.1016/j.farma.2025.07.003","DOIUrl":"https://doi.org/10.1016/j.farma.2025.07.003","url":null,"abstract":"<p><strong>Objetives: </strong>To design the patient onboarding in a multidisciplinary severe asthma unit, according to the needs identified by patients and professionals in the unit.</p><p><strong>Methods: </strong>Qualitative study using the human-centred design conducted between November 2022 and February 2023. Patients and professionals from the severe asthma unit and experts in the methodology participated. Three workshops were held. In the first, we elaborated the patient experience map, identifying positive aspects and needs. Possible solutions were devised. In the second, we selected the solutions described in a previous project applicable to onboarding and determined the key moments. In the third, we finalised the definition of the key moments, the professionals in charge in each step and the tools to be incorporated. Finally, in short sessions (sprints) we developed the necessary material and infographics.</p><p><strong>Results: </strong>We identified the main needs of patients (better control of the disease and autonomy in care, two-way conversation with professionals and receiving coordinated and personalised care) and professionals (defining, structuring, unifying and adapting the information provided to patients and managing to maintain open conversations with them). We determined that onboarding should establish a controlled welcome to the severe asthma unit, which is identifiable by patients, promotes the patient-professional relationship and the learning, use and functioning of the severe asthma unit. Previously devised solutions applicable to onboarding, such as the landing kit or the patient diary, were selected. We established the key moments of onboarding (identification consultation, initial consultation, onboarding consultation and complementary consultations), the professionals involved and the necessary information, material and infographics. Finally, we developed the design, structure and final content of the necessary tools, such as the patient diary or the asthma infographic.</p><p><strong>Conclusions: </strong>This work has allowed us to design, structure and standardise the onboarding, providing an environment that facilitates self-care and open, empathetic, two-way conversation between patients and professionals, according with the key needs expressed by both. These findings may be useful for other multidisciplinary care units.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papel del técnico de farmacia en la unidad de ensayos clínicos del servicio de farmacia de un hospital oncohematológico","authors":"Núria Farré Cabrerizo,&nbsp;Olalla Montero Pérez,&nbsp;Maria Emilia Miquel Zurita,&nbsp;Marina Badàs Moreno,&nbsp;Marta Company Martos,&nbsp;Gemma Garcia Deu,&nbsp;Jennifer Rodríguez Rojas,&nbsp;Mònica González Laguna,&nbsp;Sonia Narváez Seixa,&nbsp;Sandra Fontanals Martínez,&nbsp;Maria Perayre Badia","doi":"10.1016/j.farma.2025.02.008","DOIUrl":"10.1016/j.farma.2025.02.008","url":null,"abstract":"<div><div>In recent years, there has been a considerable increase in clinical trials in the field of oncohematology, a field in which the appearance of new drugs is continuous. In addition to the high number of clinical trials available, the growing complexity of the treatments developed for cancer is also relevant. This situation has required a notable evolution and specialization of the functions and responsibilities of pharmacy technicians in the Clinical Trials Unit of the Pharmacy Service.</div><div>This article describes the functions of the pharmacy technician in a Clinical Trial Unit of the Pharmacy Service of an oncohematological hospital, with a track record of more than 20 years of experience in Clinical Trials.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 321-327"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative review","authors":"Eva María Legido Perdices ,&nbsp;Fernando do Pazo Oubiña ,&nbsp;Elena Prado Mel ,&nbsp;Marta Miarons ,&nbsp;Betel Del Rosario García ,&nbsp;Fernando Gutiérrez Nicolás","doi":"10.1016/j.farma.2025.02.012","DOIUrl":"10.1016/j.farma.2025.02.012","url":null,"abstract":"<div><h3>Objective</h3><div>Sacituzumab govitecan is an antineoplastic therapy composed of a monoclonal antibody directed to the Trop2 antigen, conjugated to SN-38, an active metabolite of irinotecan that inhibits topoisomerase I. It is indicated for the treatment of metastatic triple-negative breast cancer in patients who have received at least two prior lines of treatment, with at least one in the metastatic context. SN-38 is eliminated by glucuronidation mediated by uridine diphosphate-glucuronosyltransferase-1A1 (UGT1A1) enzymes, present in the liver. Mutations in the <em>UGT1A1</em> gene decrease the expression of these enzymes, which increases the concentration of SN-38 and, consequently, increases the toxicity of the drug, especially in the form of neutropenia and diarrhea. This study aims to analyze the relationship between <em>UGT1A1</em> gene polymorphisms and toxicity associated with treatment with sacituzumab govitecan, in addition to reviewing the usefulness of genetic screening prior to starting therapy.</div></div><div><h3>Methods</h3><div>A non-systematic literature review was conducted on the impact of <em>UGT1A1</em> gene polymorphisms on the safety of sacituzumab govitecan treatment in patients with triple-negative breast cancer. The search included primary and secondary literature sources and communications from oncology conferences.</div></div><div><h3>Results</h3><div>Patients treated with sacituzumab govitecan with the <em>UGT1A1*28/*28</em> mutated genotype are more likely to experience grade more than 3 hematologic adverse events: neutropenia (approximate incidence of 60% compared to 40% for 1/*1 and 1/*28 genotypes), febrile neutropenia (18% homozygotes vs. 5% heterozygotes and 3% wild-type), grade more than 3 anemia (15% vs. 6% and 4%, respectively); as well as grade more than 3 diarrhea (24% vs. 13% and 6%, respectively). Additionally, treatment discontinuation rates are higher in *28/*28 individuals (6% compared to 1% heterozygotes and 2% wild-type).</div></div><div><h3>Conclusions</h3><div>Patients homozygous for the <em>UGT1A1*28</em> allele are at significantly increased risk of developing serious adverse events. Despite the clear relationship between <em>UGT1A1</em> polymorphisms and sacituzumab-govitecan toxicity, the review suggests that there is insufficient consensus on the need for systematic genetic screening. However, the findings indicate that such screening could be useful for identifying patients at risk and personalizing sacituzumab govitecan therapy.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T339-T345"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Uso fuera de indicación de olaparib en localizaciones tumorales poco frecuentes en pacientes con genes alterados de la recombinación homóloga","authors":"Héctor Carlos García-Díaz ,&nbsp;María Larrosa-Garcia ,&nbsp;Javier Gómez-Alonso ,&nbsp;Mara Cruellas ,&nbsp;Enriqueta Felip ,&nbsp;Teresa Macarulla ,&nbsp;Anna Farriols ,&nbsp;Maria J. Carreras","doi":"10.1016/j.farma.2025.04.005","DOIUrl":"10.1016/j.farma.2025.04.005","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the effectiveness and safety of olaparib off-label indications in patients with impaired homologous recombination genes and solid tumors different than those authorized.</div></div><div><h3>Methods</h3><div>A single-center, observational and retrospective study including patients treated with olaparib for off-label use. The main variables were patient characteristics, prior therapies, response to therapy, progression-free survival, overall survival and adverse events.</div></div><div><h3>Results</h3><div>A total of 6 patients were included. All patients had metastases and received 3 or more lines of prior treatment. The primary tumor locations and mutations were partner and localizer of <em>BRCA2</em> (<em>PALB2)</em> intrahepatic cholangiocarcinoma, ataxia telangiectasia mutated (<em>ATM)</em> non-small cell lung adenocarcinoma, somatic breast cancer gene (<em>sBRCA2)</em> colorectal cancer, germinal breast cancer gene 2 (<em>gBRCA2)</em> breast neuroendocrine tumor, <em>gBRCA2</em> ampullary cancer and <em>gBRCA2</em> pancreatic neuroendocrine tumor. At the end of the study, one patient was still receiving olaparib showing more than 25 months of sustained stable disease response. No novel toxicities were observed besides those included in the product information.</div></div><div><h3>Conclusions</h3><div>There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes<em>,</em> like <em>PALB2</em> and <em>ATM</em> and conditions different than those authorized such as digestive tract, neuroendocrine and lung tumors. Further research is to assess the efficacy of olaparib in these patients.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T286-T290"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Encuesta Nacional de la SEFH 2022 sobre los servicios de farmacia hospitalaria en España: recursos humanos, infraestructura, tecnología, sistemas de información, docencia e investigación","authors":"Montserrat Pérez-Encinas ,&nbsp;Eva Negro-Vega ,&nbsp;Cecilia M. Fernández-Llamazares","doi":"10.1016/j.farma.2025.08.002","DOIUrl":"10.1016/j.farma.2025.08.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To present results of the 2022 SEFH-Survey on Spanish Hospital Pharmacy Departments covering care, staffing, resources, technology, education, and research.</div></div><div><h3>Method</h3><div>A cross-sectional descriptive study via a voluntary online survey sent to 353 hospitals in Spain. Data were collected from July–December 2022. Long-stay hospitals and correctional facilities were excluded.</div></div><div><h3>Results</h3><div>Response rate was 54.1%. Public hospitals represented 62.6%. Only 10.1% of departments operated 24/7, rising to 39.3% in larger hospitals. Half lacked continuous care service. Outpatients' services operated in mornings and afternoons in 54.8% of them (78.6% in larger centers). Telepharmacy for outpatients reached 57.7% of hospitals. ISO 9000 standards were followed by 70.7% and 14.4% adopted the Joint Commission model.</div><div>Each department had on average 7.0 specialist pharmacists (8.8 in public hospitals; 3.9 in private), increasing to 13.4 in larger hospitals. Of these, 3.8 pharmacists worked at least half-time in clinical units. Pharmacy technicians were the most common non-pharmacist professionals (mean: 6.9). Including residents, 9.936 professionals worked in Hospital Pharmacy Departments nationwide.</div><div>Automated dispensing carousels averaged 0.4 (horizontal) and 1.1 (vertical) per department. Automated dispensing systems covered 19.8% of beds. Robotic outpatient dispensing existed in 20.0% of hospitals. Technology for sterile workflow was used in 45.3%, 10.0% had robotics for cytostatic compounding and 61.7% smart infusion pumps.</div><div>Pharmaceutical care was provided in emergency services in 39.8% of hospitals, rising to 67.4 in larger ones. In home hospitalization, it was offered at 32.5% of departments, rising to 60.7% in centers with over 1000 beds.</div><div>Sterile formulations were prepared in 82.3% of departments; 15.7% managed advanced therapies. Drug level monitoring was measured in 16.1%, and 43.1% issued pharmacokinetics reports. Pharmacogenetic reports were produced in 8.7%.</div><div>On average pharmacy departments attended 3.635 outpatients, totaling 1,28 million nationwide. Cytostatic preparations averaged 31,199 and 46,263 in hospitals with over 500 and 1000 beds, respectively. Clinical trials per department averaged 424.</div><div>A total of 321 pharmacists were associate university professors, 401 held board certifications, and there were 2.3 PhD holders per department.</div></div><div><h3>Conclusions</h3><div>Hospital Pharmacy Departments are advancing in clinical integration, pharmacokinetics, automation, traceability, and outpatient care, though staffing remains limited and disparities persist. Teaching is strong, yet research remains modest.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T312-T320"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Map of the residency rotations for hospital pharmacy residents in Spain","authors":"Claudia Colomer Aguilar ,&nbsp;Eva Negro-Vega ,&nbsp;Edurne Fernández de Gamarra-Martínez ,&nbsp;Beatriz Martínez Castro ,&nbsp;María Pérez Abánades ,&nbsp;Susana Redondo Capafons ,&nbsp;Covadonga Pérez Menéndez Conde","doi":"10.1016/j.farma.2025.06.010","DOIUrl":"10.1016/j.farma.2025.06.010","url":null,"abstract":"<div><h3>Objective</h3><div>Collecting updated information on the organization of Hospital Pharmacy specialty rotations in different areas across Spanish hospitals, in order to create a map of residency rotations for hospital pharmacy residents, serving as a guideline and reference for hospital pharmacy tutors.</div></div><div><h3>Method</h3><div>A cross-sectional, multicenter descriptive study on the planning of residency rotations for hospital pharmacy interns in hospitals accredited for specialized healthcare training in Spain. An online survey was designed and distributed via mailing list by the Spanish Society of Hospital Pharmacy between May and June 2024. The survey, validated and tested in a pilot sample, gathered general information about the hospital, rotations by areas of activity (year of residency, duration, complete/partial modality, shared rotations), external and elective rotations, additional training, supervision and assessment of the residents. Data were analyzed descriptively, including measures of central tendency and dispersion for quantitative variables and frequencies for categorical variables.</div></div><div><h3>Results</h3><div>The response rate was 86.8%. A basic initial rotation is present in 88.9% of hospitals, with a median duration of 6.5 weeks. Stock management, compounding, and validation and dispensing to inpatients are primarily carried out during the first year, while nutrition and oncology are concentrated in the 2nd year. Outpatient pharmaceutical care, clinical trials, medication evaluation and selection, drug information, and pharmacokinetics are conducted in the third year, whereas management/administration, primary care, and pharmaceutical care in clinical units are undertaken in the 4th year. The most common clinical rotations include Infectious Diseases (70.7%) and Hematology (67.7%). The duration of rotations varies between 1 and 9 months, with many organized as shared rotations, particularly in drug information and medication evaluation. Rotations not included in the official programme are included in 93.3% of hospitals, 91.9% of residents participate in clinical committees, and 22.2% have the opportunity to pursue a PhD.</div></div><div><h3>Conclusions</h3><div>This study shows considerable variability in the organization of training programs across hospital pharmacy teaching units in Spain.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T291-T298"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Vemurafenib for the treatment of BRAF V600 mutated glioblastoma: A case report","authors":"Irene de la Fuente Villaverde ,&nbsp;Alicia Caso González ,&nbsp;Mónica Carbajales Álvarez ,&nbsp;Alba Martínez Torrón ,&nbsp;Sergio Fernández Lastras ,&nbsp;Juan Luis García Llano ,&nbsp;Ana Lozano Blázquez","doi":"10.1016/j.farma.2025.05.010","DOIUrl":"10.1016/j.farma.2025.05.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Glioblastoma is one of the most aggressive primary brain tumors with the worst prognosis. Few therapeutic options are currently available. Vemurafenib is a kinase inhibitor that demonstrated efficacy in clinical trials for the treatment of tumors with <em>BRAF</em> V600 mutation. Its experience of use in glioblastomas is very limited.</div><div>We present the case of a patient diagnosed with BRAF V600 mutated glioblastoma who progressed to standard therapy. After starting treatment with vemurafenib in June 2022, the patient currently maintains a good clinical situation and the disease remains stable, with no progression observed.</div></div><div><h3>Discussion</h3><div>There is little literature supporting the efficacy of vemurafenib in BRAF 600 mutated glioblastomas. Published data suggest promising results, although survival in these patients remains low. This patient's progression-free survival is one of the longest documented to date.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T346-T348"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes","authors":"Héctor Carlos García-Díaz ,&nbsp;María Larrosa-Garcia ,&nbsp;Javier Gómez-Alonso ,&nbsp;Mara Cruellas ,&nbsp;Enriqueta Felip ,&nbsp;Teresa Macarulla ,&nbsp;Anna Farriols ,&nbsp;Maria J. Carreras","doi":"10.1016/j.farma.2025.02.010","DOIUrl":"10.1016/j.farma.2025.02.010","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the effectiveness and safety of olaparib off-label indications in patients with impaired homologous recombination genes and solid tumors different than those authorized.</div></div><div><h3>Methods</h3><div>A single-center, observational and retrospective study including patients treated with olaparib for off-label use. The main variables were patient characteristics, prior therapies, response to therapy, progression-free survival, overall survival and adverse events.</div></div><div><h3>Results</h3><div>A total of 6 patients were included. All patients had metastases and received 3 or more lines of prior treatment. The primary tumor locations and mutations were partner and localizer of <em>BRCA2</em> (<em>PALB2)</em> intrahepatic cholangiocarcinoma, ataxia telangiectasia mutated (<em>ATM)</em> non-small cell lung adenocarcinoma, somatic breast cancer gene (<em>sBRCA2)</em> colorectal cancer, germinal breast cancer gene 2 (<em>gBRCA2)</em> breast neuroendocrine tumor, <em>gBRCA2</em> ampullary cancer and <em>gBRCA2</em> pancreatic neuroendocrine tumor. At the end of the study, one patient was still receiving olaparib showing more than 25 months of sustained stable disease response. No novel toxicities were observed besides those included in the product information.</div></div><div><h3>Conclusions</h3><div>There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes<em>,</em> like <em>PALB2</em> and <em>ATM</em> and conditions different than those authorized such as digestive tract, neuroendocrine and lung tumors. Further research is to assess the efficacy of olaparib in these patients.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 286-290"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARN mensajero como nueva estrategia contra el cáncer","authors":"Eduardo Tejedor Tejada ,&nbsp;Begoña Gómez Pérez ,&nbsp;Garbiñe Lizeaga Cundin","doi":"10.1016/j.farma.2024.10.007","DOIUrl":"10.1016/j.farma.2024.10.007","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Page 350"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapa de las rotaciones de los farmacéuticos internos residentes de farmacia hospitalaria en España","authors":"Claudia Colomer Aguilar ,&nbsp;Eva Negro-Vega ,&nbsp;Edurne Fernández de Gamarra-Martínez ,&nbsp;Beatriz Martínez Castro ,&nbsp;María Pérez Abánades ,&nbsp;Susana Redondo Capafons ,&nbsp;Covadonga Pérez Menéndez Conde","doi":"10.1016/j.farma.2025.03.014","DOIUrl":"10.1016/j.farma.2025.03.014","url":null,"abstract":"<div><h3>Objective</h3><div>Collecting updated information on the organization of Hospital Pharmacy specialty rotations in different areas across Spanish hospitals, in order to create a map of residency rotations for hospital pharmacy interns, serving as a guideline and reference for hospital pharmacy tutors.</div></div><div><h3>Method</h3><div>A cross-sectional, multicenter descriptive study on the planning of residency rotations for hospital pharmacy interns in hospitals accredited for specialized healthcare training in Spain. An online survey was designed and distributed via mailing list by the Spanish Society of Hospital Pharmacy between May and June 2024. The survey, validated and tested in a pilot sample, gathered general information about the hospital, rotations by areas of activity (year of residency, duration, complete/partial modality, shared rotations), external and elective rotations, additional training, supervision and assessment of the residents. Data were analyzed descriptively, including measures of central tendency and dispersion for quantitative variables and frequencies for categorical variables.</div></div><div><h3>Results</h3><div>The response rate was 86.8%. A basic initial rotation is present in 88.9% of hospitals, with a median duration of 6.5 weeks. Stock management, compounding, and validation and dispensing to inpatients are primarily carried out during the first year, while nutrition and oncology are concentrated in the 2nd year. Outpatient pharmaceutical care, clinical trials, medication evaluation and selection, drug information, and pharmacokinetics are conducted in the third year, whereas management/leadership, primary care, and pharmaceutical care in clinical units are undertaken in the 4th year. The most common clinical rotations include Infectious Diseases (70.7%) and Hematology (67.7%). The duration of rotations varies between 1 and 9 months, with many organized as shared rotations, particularly in drug information and medication evaluation. Non-programmed rotations are included in 93.3% of hospitals, 91.9% of residents participate in clinical committees, and 22.2% have the opportunity to pursue a PhD.</div></div><div><h3>Conclusions</h3><div>This study shows considerable variability in the organization of training programs across hospital pharmacy teaching units in Spain.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 291-298"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}